Study analysis · Frontiers in Cardiovascular Medicine · 2026
A blood pressure number below 120 was linked to 12 fewer heart attacks, strokes, or heart failures per 100 high-risk patients—but the benefit faded after 75.
In high-risk patients, those who got their systolic blood pressure under 120 had fewer heart problems than those who stayed around 130-139, but older patients didn't see the same benefit.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This is a look-back study, not a randomized experiment. It shows that people who ended up with lower blood pressure also had fewer heart problems, but it can't prove that lowering blood pressure caused the improvement. Other differences between the groups could explain the results.
What’s the bottom line?
In a study of 180 high-risk patients with high blood pressure, those who got their systolic blood pressure below 120 had fewer heart attacks, strokes, and heart failures than those who stayed at 130-139. The benefit was biggest for people with diabetes or kidney disease, but older patients over 75 didn't seem to benefit as much. Side effects like low blood pressure were a bit more common with the tighter control, but not serious.
How strong is this study?
The study uses real patient records from one hospital, which is useful for seeing what happens in everyday care. But it's small and patients weren't randomly assigned to blood pressure targets, so we can't be sure the groups were truly similar. That makes the results less reliable than a randomized trial.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
46 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=180)+11.9/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 558 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Retrospective cohort with no randomization; groups defined by achieved systolic blood pressure, not assigned treatment; high risk of confounding by indication and unmeasured confounders; cannot establish causal effect of intensive blood pressure management on cardiovascular outcomes.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were declared; the study appears to be independently conducted.
No COI or funding section present. The Results section contains an unrelated heading 'Anti-proliferative activity of vanoxerine in AML cells', which may indicate a data integrity or manuscript preparation issue unrelated to COI.
Key takeaways
- 01
Patients with SBP <120 had 14.8% MACE vs 26.5% in the 130-139 group (p=0.03).
- 02
That's an absolute difference of 11.7 percentage points, or about 12 fewer events per 100 patients over 18 months.
- 03
For diabetes/CKD, there was a 30% relative risk reduction (absolute not reported).
- 04
Side effects: 9.3% vs 4.8% (p=0.60, not significant).
- 05
If 100 high-risk patients aimed for SBP <120 instead of 130-139, about 12 fewer would have a heart attack, stroke, or heart failure over 18 months.
- 06
However, this is an observational study, so it doesn't prove cause and effect.
- 07
The absolute benefit for people with diabetes or kidney disease is not reported, but the relative reduction was 30%.
Surprising findings
- The benefit of intensive blood pressure lowering was attenuated in patients over 75, with no statistically significant reduction in MACE.Many guidelines and trials like SPRINT suggest older adults may benefit from intensive control, but this real-world study found no significant benefit in those over 75.
- Adverse events were higher in the intensive group but the difference was not statistically significant (9.3% vs 4.8%, p=0.60).You might expect that pushing blood pressure lower would cause significantly more hypotension and kidney problems, but this small study couldn't detect a significant difference.
- Sex did not modify the benefit of intensive blood pressure lowering; men and women experienced similar magnitudes of benefit.Cardiovascular risk and treatment responses often differ by sex, so finding no difference is notable.
Practical takeaways
If you have high-risk hypertension with diabetes or chronic kidney disease, talk to your doctor about whether a systolic blood pressure target below 120 might be appropriate for you.
This was an observational study with no randomization; absolute risk reduction was not reported for these subgroups. Do not change medications without medical advice.
low to medium confidenceIf you are over 75, be cautious about aggressively pursuing a systolic blood pressure below 120; discuss risks and benefits with your clinician.
The subgroup over 75 was small and underpowered, so lack of significant benefit does not prove harm or no benefit.
low confidenceIf you aim for a lower blood pressure target, expect to need more medications and monitoring for side effects like dizziness or kidney changes.
Adverse events were numerically higher but not statistically significant in this small study; medication dose and adherence data were not available.
medium confidenceDo not change your blood pressure medications based on this single study. Use it as a conversation starter with your doctor, not a prescription.
Retrospective design, small sample (n=180), and lack of data on medication dose and adherence limit causal conclusions.
high confidenceWhy this study matters
The 120 vs 130-139 showdown
In this retrospective cohort of 180 high-risk hypertensive patients, major adverse cardiovascular events (MACE) occurred in 14.8% of those achieving SBP <120 mmHg versus 26.5% of those at 130-139 mmHg (p=0.03) over a median 18 months. That is an absolute risk difference of 11.7 percentage points, or about 12 fewer events per 100 patients over 18 months. The relative reduction is about 44% (computed), but the study did not report confidence intervals and is observational.
Many people with high blood pressure wonder how low they should go. This study suggests a big potential benefit from tighter control in high-risk patients.
Diabetes and kidney disease win big
Patients with diabetes or chronic kidney disease had a 30% relative risk reduction in MACE when achieving SBP <120 mmHg compared to standard control. The absolute risk reduction for these subgroups was not reported, so we don't know exactly how many events were prevented per 100 patients.
People with diabetes or kidney disease are already at high cardiovascular risk. This finding suggests they may benefit most from aggressive blood pressure lowering.
The age 75 caveat
The cardiovascular benefit of targeting SBP <120 mmHg was attenuated in patients over 75, with no statistically significant reduction in MACE compared to standard control. The study notes 'attenuation of benefits in elderly patients, i.e., where age was over 75.'
Many older adults are told to lower their blood pressure aggressively, but this study suggests the benefit may not hold after 75—and side effects like hypotension may be more concerning.
More pills, more side effects
Patients achieving SBP <120 took more antihypertensive medications on average (2.9 vs 2.2, p=0.01), were more likely on ACE inhibitors/ARBs (67.4% vs 54.5%, p=0.04), and more often on three or more drug classes (44.6% vs 21.6%, p=0.003). Adverse events were numerically higher in the intensive group (9.3% vs 4.8%, p=0.60 in abstract), but not statistically significant.
Getting to a lower blood pressure often requires more medication, which can mean more cost, more monitoring, and more side effects. This study quantifies that tradeoff.
Real-world evidence, but not proof
This was a retrospective cohort study, not a randomized trial. Patients were grouped by achieved SBP, not randomly assigned. The authors state findings are 'hypothesis-generating rather than definitive evidence of treatment effect.'
It's easy to jump to conclusions from observational data. This study reminds us that association is not causation—even when the numbers look impressive.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In a study of 180 high-risk patients with high blood pressure, those who got their systolic blood pressure below 120 had fewer heart attacks, strokes, and heart failures than those who stayed at 130-139. The benefit was biggest for people with diabetes or kidney disease, but older patients over 75 didn't seem to benefit as much. Side effects like low blood pressure were a bit more common with the tighter control, but not serious.
Research results
Patients with SBP <120 had 14.8% MACE vs 26.5% in the 130-139 group (p=0.03). That's an absolute difference of 11.7 percentage points, or about 12 fewer events per 100 patients over 18 months. For diabetes/CKD, there was a 30% relative risk reduction (absolute not reported). Side effects: 9.3% vs 4.8% (p=0.60, not significant).
What this means - more context
If 100 high-risk patients aimed for SBP <120 instead of 130-139, about 12 fewer would have a heart attack, stroke, or heart failure over 18 months. However, this is an observational study, so it doesn't prove cause and effect. The absolute benefit for people with diabetes or kidney disease is not reported, but the relative reduction was 30%.
Evaluate the association between achieved systolic blood pressure (SBP) levels and cardiovascular outcomes in high-risk hypertensive patients.
In this retrospective cohort of 180 high-risk hypertensive patients, those achieving SBP <120 mmHg had significantly fewer major adverse cardiovascular events (MACE) compared to those with SBP 130-139 mmHg (14.8% vs 26.5%, p=0.03) over a median 18-month follow-up. The relative risk reduction was 30% in patients with diabetes or chronic kidney disease, but benefits were attenuated in those over 75. Adverse events were slightly higher in the intensive group (9.3% vs 4.8%) but not statistically significant (p=0.60).
Methods Used
Retrospective cohort study from January 2022 to December 2024 at a tertiary care facility in Shanghai, China. 180 high-risk hypertensive patients were categorized by achieved SBP during follow-up: <120 mmHg (n=92) vs 130-139 mmHg (n=88). Primary endpoint was composite MACE (myocardial infarction, stroke, heart failure, cardiovascular death/hospitalization). Median follow-up was 18 months.
Main Finding
Lower achieved SBP (<120 mmHg) was associated with a significantly lower incidence of MACE compared to SBP 130-139 mmHg (14.8% vs 26.5%; p=0.03), corresponding to an absolute risk difference of 11.7 percentage points, or about 12 fewer cardiovascular events per 100 patients over 18 months. The relative risk reduction was 30% in patients with diabetes or chronic kidney disease (absolute risk reduction not reported). Benefits were attenuated in patients over 75 years. Adverse events were numerically higher in the intensive group (9.3% vs 4.8%) but not statistically significant (p=0.60).
Confidence Level
Low to moderate due to retrospective design, small sample size (n=180), lack of randomization, potential unmeasured confounding, and no data on medication adherence or dose. Authors state findings are hypothesis-generating.
Study Flags
Red Flags
- •Retrospective design precludes causal inference.
- •Small sample size (n=180) limits power, especially for subgroup analyses.
- •Lack of data on medication dose, adherence, and potential unmeasured confounding.
Surprising Findings
The benefit of intensive blood pressure lowering was attenuated in patients over 75, with no statistically significant reduction in MACE.
Many guidelines and trials like SPRINT suggest older adults may benefit from intensive control, but this real-world study found no significant benefit in those over 75.
Practical Takeaways
If you have high-risk hypertension with diabetes or chronic kidney disease, talk to your doctor about whether a systolic blood pressure target below 120 might be appropriate for you.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 558 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This is a look-back study, not a randomized experiment. It shows that people who ended up with lower blood pressure also had fewer heart problems, but it can't prove that lowering blood pressure caused the improvement. Other differences between the groups could explain the results.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Real-world data reflecting routine clinical practice.
- Focus on high-risk hypertensive patients often underrepresented in trials.
- Composite MACE outcome with median 18-month follow-up.
Weaknesses
- Retrospective, non-randomized design with groups defined by achieved SBP, leading to confounding by indication.
- No randomization or blinding; treatment allocation not controlled.
- Small sample size (n=180) and underpowered subgroup analyses.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In a study of 180 high-risk patients with high blood pressure, those who got their systolic blood pressure below 120 had fewer heart attacks, strokes, and heart failures than those who stayed at 130-139. The benefit was biggest for people with diabetes or kidney disease, but older patients over 75 didn't seem to benefit as much. Side effects like low blood pressure were a bit more common with the tighter control, but not serious.
Research results
Patients with SBP <120 had 14.8% MACE vs 26.5% in the 130-139 group (p=0.03). That's an absolute difference of 11.7 percentage points, or about 12 fewer events per 100 patients over 18 months. For diabetes/CKD, there was a 30% relative risk reduction (absolute not reported). Side effects: 9.3% vs 4.8% (p=0.60, not significant).
What this means - more context
If 100 high-risk patients aimed for SBP <120 instead of 130-139, about 12 fewer would have a heart attack, stroke, or heart failure over 18 months. However, this is an observational study, so it doesn't prove cause and effect. The absolute benefit for people with diabetes or kidney disease is not reported, but the relative reduction was 30%.
Evaluate the association between achieved systolic blood pressure (SBP) levels and cardiovascular outcomes in high-risk hypertensive patients.
In this retrospective cohort of 180 high-risk hypertensive patients, those achieving SBP <120 mmHg had significantly fewer major adverse cardiovascular events (MACE) compared to those with SBP 130-139 mmHg (14.8% vs 26.5%, p=0.03) over a median 18-month follow-up. The relative risk reduction was 30% in patients with diabetes or chronic kidney disease, but benefits were attenuated in those over 75. Adverse events were slightly higher in the intensive group (9.3% vs 4.8%) but not statistically significant (p=0.60).
Methods Used
Retrospective cohort study from January 2022 to December 2024 at a tertiary care facility in Shanghai, China. 180 high-risk hypertensive patients were categorized by achieved SBP during follow-up: <120 mmHg (n=92) vs 130-139 mmHg (n=88). Primary endpoint was composite MACE (myocardial infarction, stroke, heart failure, cardiovascular death/hospitalization). Median follow-up was 18 months.
Main Finding
Lower achieved SBP (<120 mmHg) was associated with a significantly lower incidence of MACE compared to SBP 130-139 mmHg (14.8% vs 26.5%; p=0.03), corresponding to an absolute risk difference of 11.7 percentage points, or about 12 fewer cardiovascular events per 100 patients over 18 months. The relative risk reduction was 30% in patients with diabetes or chronic kidney disease (absolute risk reduction not reported). Benefits were attenuated in patients over 75 years. Adverse events were numerically higher in the intensive group (9.3% vs 4.8%) but not statistically significant (p=0.60).
Confidence Level
Low to moderate due to retrospective design, small sample size (n=180), lack of randomization, potential unmeasured confounding, and no data on medication adherence or dose. Authors state findings are hypothesis-generating.
Study Flags
Red Flags
- •Retrospective design precludes causal inference.
- •Small sample size (n=180) limits power, especially for subgroup analyses.
- •Lack of data on medication dose, adherence, and potential unmeasured confounding.
Surprising Findings
The benefit of intensive blood pressure lowering was attenuated in patients over 75, with no statistically significant reduction in MACE.
Many guidelines and trials like SPRINT suggest older adults may benefit from intensive control, but this real-world study found no significant benefit in those over 75.
Practical Takeaways
If you have high-risk hypertension with diabetes or chronic kidney disease, talk to your doctor about whether a systolic blood pressure target below 120 might be appropriate for you.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 558 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This is a look-back study, not a randomized experiment. It shows that people who ended up with lower blood pressure also had fewer heart problems, but it can't prove that lowering blood pressure caused the improvement. Other differences between the groups could explain the results.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Real-world data reflecting routine clinical practice.
- Focus on high-risk hypertensive patients often underrepresented in trials.
- Composite MACE outcome with median 18-month follow-up.
Weaknesses
- Retrospective, non-randomized design with groups defined by achieved SBP, leading to confounding by indication.
- No randomization or blinding; treatment allocation not controlled.
- Small sample size (n=180) and underpowered subgroup analyses.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study uses real patient records from one hospital, which is useful for seeing what happens in everyday care. But it's small and patients weren't randomly assigned to blood pressure targets, so we can't be sure the groups were truly similar. That makes the results less reliable than a randomized trial.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
46 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=180)+11.9/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 558 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Retrospective cohort with no randomization; groups defined by achieved systolic blood pressure, not assigned treatment; high risk of confounding by indication and unmeasured confounders; cannot establish causal effect of intensive blood pressure management on cardiovascular outcomes.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were declared; the study appears to be independently conducted.
No COI or funding section present. The Results section contains an unrelated heading 'Anti-proliferative activity of vanoxerine in AML cells', which may indicate a data integrity or manuscript preparation issue unrelated to COI.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
2 researchersIf this is your work, this is how we attribute it on Fit Body Science. Baihui Tang is listed as the lead author.